{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:44:56Z","timestamp":1793835896372,"version":"4.6.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>to describe 10-year changes in health measures and cardiovascular risk among transmasculine adults on testosterone-based Gender-Affirming Hormone Therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>this is a single-centre, longitudinal cohort study of transmasculine adults who began Gender-Affirming Hormone Therapy and were followed-up for a total of 10 years according to standard clinical practice, which includes yearly visits with complete physical examinations, blood tests, and assessment of body composition. For participants aged 35 years or older, we estimated the 10-year cardiovascular risk, and then compared it with age-matched people from the general population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>57 participants completed 10 years of follow-up. Nearly half smoked and few were physically active. Haemoglobin and haematocrit rose early and then stabilised within usual ranges; very high values were uncommon. Fasting glucose, insulin, and blood pressure did not change meaningfully. The lipid profile worsened: LDL, total cholesterol and triglycerides increased, and HDL decreased throughout the study period. Weight, body mass index, waist circumference, and waist-to-hip ratio increased. Body composition showed higher lean mass and trunk fat, with a shift toward android fat distribution. No major cardiovascular events were recorded. One participant developed atrial fibrillation. Metabolic syndrome by female criteria became more frequent. cardiovascular risk was higher than cisgender women but similar to cisgender men at ages 35\u201344; at ages 45\u201354 it was lower than cisgender men.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Over 10 years, testosterone-based Gender-Affirming Hormone Therapy is linked to less favorable lipid profiles and body composition patterns, supporting constant monitoring, risk-factor treatment, and lifestyle support.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s40618-026-02906-3","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T04:53:15Z","timestamp":1779425595000},"page":"2361-2374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Changes in cardiometabolic risk factors in transmasculine individuals over 10 years of Gender-Affirming Hormone Therapy"],"prefix":"10.1007","volume":"49","author":[{"given":"Martino","family":"Azzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Lami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Dones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arrigo Francesco Giuseppe","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Siconolfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Seracchioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0061-9834","authenticated-orcid":false,"given":"Maria Cristina","family":"Meriggiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2906_CR1","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1210\/jc.2012-1187","volume":"97","author":"E Van Caenegem","year":"2012","unstructured":"Van Caenegem E, Wierckx K, Taes Y, Dedecker D, Van De Peer F, Toye K et al (2012) Bone mass, bone geometry, and body composition in female-to-male transsexual persons after long-term cross-sex hormonal therapy. J Clin Endocrinol Metab 97:2503\u201311. https:\/\/doi.org\/10.1210\/jc.2012-1187","journal-title":"J Clin Endocrinol Metab"},{"key":"2906_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3233\/JRS-200087","volume":"34","author":"C Milionis","year":"2023","unstructured":"Milionis C, Ilias I, Venaki E, Koukkou E (2023) The metabolic effects of hormonal treatment in transgender males: safety of the testosterone gender-affirming therapy. Int J Risk Saf Med 34:21\u201328. https:\/\/doi.org\/10.3233\/JRS-200087","journal-title":"Int J Risk Saf Med"},{"key":"2906_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.maturitas.2017.10.012","volume":"107","author":"R Vita","year":"2018","unstructured":"Vita R, Settineri S, Liotta M, Benvenga S, Trimarchi F (2018) Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: a cohort study. Maturitas 107:92\u20136. https:\/\/doi.org\/10.1016\/j.maturitas.2017.10.012","journal-title":"Maturitas"},{"key":"2906_CR4","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/cen.13821","volume":"89","author":"G Gava","year":"2018","unstructured":"Gava G, Mancini I, Cerpolini S, Baldassarre M, Seracchioli R, Meriggiola MC (2018) Testosterone undecanoate and testosterone enanthate injections are both effective and safe in transmen over 5 years of administration. Clin Endocrinol (Oxf) 89:878\u2013886. https:\/\/doi.org\/10.1111\/cen.13821","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2906_CR5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/jsm.12571","volume":"11","author":"K Wierckx","year":"2014","unstructured":"Wierckx K, Van Caenegem E, Schreiner T, Haraldsen I, Fisher A, Toye K et al (2014) Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European Network for the Investigation of Gender Incongruence. J Sex Med 11:1999\u20132011. https:\/\/doi.org\/10.1111\/jsm.12571","journal-title":"J Sex Med"},{"key":"2906_CR6","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1161\/HYPERTENSIONAHA.120.16839","volume":"77","author":"K Banks","year":"2021","unstructured":"Banks K, Kyinn M, Leemaqz SY, Sarkodie E, Goldstein D, Irwig MS (2021) Blood pressure effects of gender-affirming hormone therapy in transgender and gender-diverse adults. Hypertension 77:2066\u20132074. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.16839","journal-title":"Hypertension"},{"key":"2906_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1089\/lgbt.2015.0058","volume":"3","author":"GR Brown","year":"2015","unstructured":"Brown GR, Jones KT (2015) Mental health and medical health disparities in 5135 transgender veterans receiving healthcare in the Veterans Health Administration: a case\u2013control study. LGBT Health 3:122\u2013131. https:\/\/doi.org\/10.1089\/lgbt.2015.0058","journal-title":"LGBT Health"},{"key":"2906_CR8","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1089\/lgbt.2021.0242","volume":"9","author":"DJ Connolly","year":"2022","unstructured":"Connolly DJ, Davies E, Lynskey M, Maier LJ, Ferris JA, Barratt MJ et al (2022) Differences in alcohol and other drug use and dependence between transgender and cisgender participants from the 2018 Global Drug Survey. LGBT Health 9:534\u201342. https:\/\/doi.org\/10.1089\/lgbt.2021.0242","journal-title":"LGBT Health"},{"key":"2906_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/nu16183139","author":"C Santangelo","year":"2024","unstructured":"Santangelo C, Marconi M, Ruocco A, Ristori J, Bonadonna S, Pivonello R et al (2024) Dietary habits, physical activity and body mass index in transgender and gender diverse adults in Italy: a voluntary sampling observational study. Nutrients. https:\/\/doi.org\/10.3390\/nu16183139","journal-title":"Nutrients"},{"key":"2906_CR10","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S2213-8587(21)00185-6","volume":"9","author":"CJ de Blok","year":"2021","unstructured":"de Blok CJ, Wiepjes CM, van Velzen DM, Staphorsius AS, Nota NM, Gooren LJ et al (2021) Mortality trends over five decades in adult transgender people receiving hormone treatment: a report from the Amsterdam cohort of gender dysphoria. Lancet Diabetes Endocrinol 9:663\u201370. https:\/\/doi.org\/10.1016\/S2213-8587(21)00185-6","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2906_CR11","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/eurjpc\/zwac133","volume":"29","author":"MA Karalexi","year":"2022","unstructured":"Karalexi MA, Frisell T, Cnattingius S, Holmberg D, Holmberg M, Kollia N et al (2022) Cardiovascular outcomes in transgender individuals in Sweden after initiation of gender-affirming hormone therapy. Eur J Prev Cardiol 29:2017\u201326. https:\/\/doi.org\/10.1093\/eurjpc\/zwac133","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"2906_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.19696","volume":"7","author":"L Hashemi","year":"2024","unstructured":"Hashemi L, Marijic Buljubasic A, Budoff MJ, Copeland LA, Jackson NJ, Jasuja GK et al (2024) Gender-affirming hormone treatment and metabolic syndrome among transgender veterans. JAMA Netw Open e2419696. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.19696","journal-title":"JAMA Netw Open"},{"key":"2906_CR13","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1215\/00703370-9942002","volume":"59","author":"LD Hughes","year":"2022","unstructured":"Hughes LD, King WM, Gamarel KE, Geronimus AT, Panagiotou OA, Hughto JMW (2022) Differences in all-cause mortality among transgender and non-transgender people enrolled in private insurance. Demography 59:1023\u20131043. https:\/\/doi.org\/10.1215\/00703370-9942002","journal-title":"Demography"},{"key":"2906_CR14","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1161\/CIRCULATIONAHA.118.038584","volume":"139","author":"NM Nota","year":"2019","unstructured":"Nota NM, Wiepjes CM, De Blok CJM, Gooren LJG, Kreukels BPC, Den Heijer M (2019) Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy: results from a large cohort study. Circulation 139:1461\u20132. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.038584","journal-title":"Circulation"},{"key":"2906_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.005597","author":"T Alzahrani","year":"2019","unstructured":"Alzahrani T, Nguyen T, Ryan A, Dwairy A, McCaffrey J, Yunus R et al (2019) Cardiovascular disease risk factors and myocardial infarction in the transgender population. Circ Cardiovasc Qual Outcomes. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.119.005597","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2906_CR16","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1210\/jc.2017-01658","volume":"102","author":"WC Hembree","year":"2017","unstructured":"Hembree WC, Cohen-Kettenis PT, Gooren L, Hannema SE, Meyer WJ, Murad MH et al (2017) Endocrine treatment of gender-dysphoric\/ gender-incongruent persons: an endocrine society\u2217clinical practice guideline. J Clin Endocrinol Metab 102:3869\u2013903. https:\/\/doi.org\/10.1210\/jc.2017-01658","journal-title":"J Clin Endocrinol Metab"},{"key":"2906_CR17","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","volume":"23","author":"E Coleman","year":"2022","unstructured":"Coleman E, Radix AE, Bouman WP, Brown GR, de Vries ALC, Deutsch MB et al (2022) Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgend Health 23:S1-259. https:\/\/doi.org\/10.1080\/26895269.2022.2100644","journal-title":"Int J Transgend Health"},{"key":"2906_CR18","unstructured":"World Health Organization (2002) https:\/\/www.who.int\/teams\/noncommunicable-diseases\/surveillance\/systems-tools\/steps (accessed April 11, 2025)"},{"key":"2906_CR19","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/j.1365-2605.2010.01122.x","volume":"34","author":"C Pelusi","year":"2011","unstructured":"Pelusi C, Costantino A, Cerpolini S, Pelusi G, Meriggiola MC, Pasquali R (2011) A placebo-controlled, randomized clinical trial using testosterone undecanoate with injectable norethisterone enanthate: effect on anthropometric, metabolic and biochemical parameters. Int J Androl 34:548\u2013555. https:\/\/doi.org\/10.1111\/j.1365-2605.2010.01122.x","journal-title":"Int J Androl"},{"key":"2906_CR20","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1210\/jcem.84.10.6079","volume":"84","author":"A Vermeulen","year":"1999","unstructured":"Vermeulen A, Verdonck L, Kaufman JM (1999) A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666\u201372","journal-title":"J Clin Endocrinol Metab"},{"key":"2906_CR21","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.2337\/dc25-SREV","volume":"48","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee (2024) Summary of Revisions: Standards of Care in Diabetes\u20142025. Diabetes Care 48:S6-13. https:\/\/doi.org\/10.2337\/dc25-SREV","journal-title":"Diabetes Care"},{"key":"2906_CR22","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al (2020) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Eur Heart J 41:111\u2013188. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455","journal-title":"Eur Heart J"},{"key":"2906_CR23","unstructured":"World Health Organization WHO Guidelines on Physical Activity and Sedentary Behaviour. n.d"},{"key":"2906_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4158\/EP.9.S2.5","volume":"9","author":"D Einhorn","year":"2003","unstructured":"Einhorn D (2003) American College of Endocrinology Position Statement on the Insulin Resistance Syndrome *. Endocr Pract 9:5\u201321. https:\/\/doi.org\/10.4158\/EP.9.S2.5","journal-title":"Endocr Pract"},{"key":"2906_CR25","first-page":"393","volume":"40","author":"L PALMIERI","year":"2004","unstructured":"Palmieri L, Panico S, Vanuzzo D, Ferrario M (2004) La valutazione del rischio cardiovascolare globale assoluto: il punteggio individuale del progetto CUORE. Ann Ist Super Sanita 40:393\u2013399","journal-title":"Ann Ist Super Sanita"},{"key":"2906_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264778","author":"C Donfrancesco","year":"2022","unstructured":"Donfrancesco C, Profumo E, Lo Noce C, Minutoli D, Di Lonardo A, Buttari B et al (2022) Trends of overweight, obesity and anthropometric measurements among the adult population in Italy: the CUORE Project health examination surveys 1998, 2008, and 2018. PLoS One. https:\/\/doi.org\/10.1371\/journal.pone.0264778","journal-title":"PLoS One"},{"key":"2906_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare12040475","author":"C Donfrancesco","year":"2024","unstructured":"Donfrancesco C, Buttari B, Marcozzi B, Sieri S, Di Lonardo A, Lo Noce C et al (2024) Nutrition, physical activity and smoking habit in the Italian general adult population: CUORE Project health examination survey 2018\u20132019. Healthcare (Basel). https:\/\/doi.org\/10.3390\/healthcare12040475","journal-title":"Healthcare (Basel)"},{"key":"2906_CR28","unstructured":"Istituto Superiore di Sanit\u00e0 (2025) CuoreData n.d. https:\/\/www.cuore.iss.it\/indagini\/CuoreData"},{"key":"2906_CR29","doi-asserted-by":"publisher","first-page":"4266","DOI":"10.1002\/sim.9505","volume":"41","author":"AI Mundo","year":"2022","unstructured":"Mundo AI, Tipton JR, Muldoon TJ (2022) Generalized additive models to analyze nonlinear trends in biomedical longitudinal data using R: beyond repeated measures ANOVA and linear mixed models. Stat Med 41:4266\u20134283. https:\/\/doi.org\/10.1002\/sim.9505","journal-title":"Stat Med"},{"key":"2906_CR30","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/cen.15223","volume":"103","author":"S Sinju","year":"2025","unstructured":"Sinju S, Sridhar S, Sreenivasan P, Paramasivam S, Varadarajan G, Mahalakshmi NK et al (2025) A randomized controlled trial comparing testosterone enanthate and testosterone undecanoate as a gender affirming hormonal therapy in trans males. Clin Endocrinol (Oxf) 103:89\u201396. https:\/\/doi.org\/10.1111\/cen.15223","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2906_CR31","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1111\/jsm.12698","volume":"11","author":"C Pelusi","year":"2014","unstructured":"Pelusi C, Costantino A, Martelli V, Lambertini M, Bazzocchi A, Ponti F et al (2014) Effects of three different testosterone formulations in female-to-male transsexual persons. J Sex Med 11:3002\u201311. https:\/\/doi.org\/10.1111\/jsm.12698","journal-title":"J Sex Med"},{"key":"2906_CR32","doi-asserted-by":"publisher","unstructured":"Cohen J (1988) Statistical Power Analysis for the Behavioral Sciences. Routledge. https:\/\/doi.org\/10.4324\/9780203771587","DOI":"10.4324\/9780203771587"},{"key":"2906_CR33","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.metabol.2014.05.005","volume":"63","author":"CJ Glueck","year":"2014","unstructured":"Glueck CJ, Wang P (2014) Testosterone therapy, thrombosis, thrombophilia, cardiovascular events. Metabolism 63:989\u2013994. https:\/\/doi.org\/10.1016\/j.metabol.2014.05.005","journal-title":"Metabolism"},{"key":"2906_CR34","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1111\/jsm.12571","volume":"11","author":"K Wierckx","year":"2014","unstructured":"Wierckx K, Van Caenegem E, Schreiner T, Haraldsen I, Fisher A, Toye K et al (2014) Cross-sex hormone therapy in trans persons is safe and effective at short\u2010time follow\u2010up: results from the European Network for the Investigation of Gender Incongruence. J Sex Med 11:1999\u20132011. https:\/\/doi.org\/10.1111\/jsm.12571","journal-title":"J Sex Med"},{"key":"2906_CR35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.thromres.2021.09.005","volume":"207","author":"M Oakes","year":"2021","unstructured":"Oakes M, Arastu A, Kato C, Somers J, Holly HD, Elstrott BK et al (2021) Erythrocytosis and thromboembolic events in transgender individuals receiving gender-affirming testosterone. Thromb Res 207:96\u20138. https:\/\/doi.org\/10.1016\/j.thromres.2021.09.005","journal-title":"Thromb Res"},{"key":"2906_CR36","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s10557-012-6402-4","volume":"26","author":"AQ Cowan","year":"2012","unstructured":"Cowan AQ, Cho DJ, Rosenson RS (2012) Importance of blood rheology in the pathophysiology of atherothrombosis. Cardiovasc Drugs Ther 26:339\u2013348. https:\/\/doi.org\/10.1007\/s10557-012-6402-4","journal-title":"Cardiovasc Drugs Ther"},{"key":"2906_CR37","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/eurheartj\/ehw550","volume":"38","author":"M Koupenova","year":"2017","unstructured":"Koupenova M, Kehrel BE, Corkrey HA, Freedman JE (2017) Thrombosis and platelets: an update. Eur Heart J 38:785\u2013791. https:\/\/doi.org\/10.1093\/eurheartj\/ehw550","journal-title":"Eur Heart J"},{"key":"2906_CR38","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/ijan.1995.18.5.237","volume":"18","author":"MC Meriggiola","year":"1995","unstructured":"Meriggiola MC, Marcovina S, Paulsen CA, Bremner WJ (1995) Testosterone enanthate at a dose of 200 mg\/week decreases HDL-cholesterol levels in healthy men. Int J Androl 18:237\u2013242. https:\/\/doi.org\/10.1111\/ijan.1995.18.5.237","journal-title":"Int J Androl"},{"key":"2906_CR39","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1210\/jc.2017-02243","volume":"103","author":"ER III Mohler","year":"2018","unstructured":"Mohler ER III, Ellenberg SS, Lewis CE, Wenger NK, Budoff MJ, Lewis MR et al (2018) The effect of testosterone on cardiovascular biomarkers in the Testosterone Trials. J Clin Endocrinol Metab 103:681\u20138. https:\/\/doi.org\/10.1210\/jc.2017-02243","journal-title":"J Clin Endocrinol Metab"},{"key":"2906_CR40","doi-asserted-by":"publisher","first-page":"E1172","DOI":"10.1152\/ajpendo.2001.281.6.E1172","volume":"281","author":"S Bhasin","year":"2001","unstructured":"Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N et al (2001) Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab 281:E1172-81. https:\/\/doi.org\/10.1152\/ajpendo.2001.281.6.E1172","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2906_CR41","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1111\/joim.20039","volume":"297","author":"TR Lundberg","year":"2025","unstructured":"Lundberg TR, Tryfonos A, Eriksson LMJ, Rundqvist H, Rullman E, Holmberg M et al (2025) Longitudinal changes in regional fat and muscle composition and cardiometabolic biomarkers over 5 years of hormone therapy in transgender individuals. J Intern Med 297:156\u201372. https:\/\/doi.org\/10.1111\/joim.20039","journal-title":"J Intern Med"},{"key":"2906_CR42","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jacl.2022.11.010","volume":"17","author":"SY Leemaqz","year":"2023","unstructured":"Leemaqz SY, Kyinn M, Banks K, Sarkodie E, Goldstein D, Irwig MS (2023) Lipid profiles and hypertriglyceridemia among transgender and gender diverse adults on gender-affirming hormone therapy. J Clin Lipidol 17:103\u2013111. https:\/\/doi.org\/10.1016\/j.jacl.2022.11.010","journal-title":"J Clin Lipidol"},{"key":"2906_CR43","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1001\/jamapediatrics.2020.5620","volume":"175","author":"K Millington","year":"2021","unstructured":"Millington K, Finlayson C, Olson-Kennedy J, Garofalo R, Rosenthal SM, Chan Y-M (2021) Association of high-density lipoprotein cholesterol with sex steroid treatment in transgender and gender-diverse youth. JAMA Pediatr 175:520\u2013521. https:\/\/doi.org\/10.1001\/jamapediatrics.2020.5620","journal-title":"JAMA Pediatr"},{"issue":"7","key":"2906_CR44","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae745","volume":"110","author":"Y Lei","year":"2024","unstructured":"Lei Y, Wiik A, Connelly MA, Lindberg L, Andersson DP, Arver S et al (2024) Cardiometabolic risk assessment in transgender individuals\u2014differential effect of sex hormones and sex chromosomes. J Clin Endocrinol Metab dgae745. https:\/\/doi.org\/10.1210\/clinem\/dgae745","journal-title":"J Clin Endocrinol Metab"},{"key":"2906_CR45","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.atherosclerosis.2021.03.008","volume":"323","author":"DM van Velzen","year":"2021","unstructured":"van Velzen DM, Adorni MP, Zimetti F, Strazzella A, Simsek S, Sirtori CR et al (2021) The effect of transgender hormonal treatment on high density lipoprotein cholesterol efflux capacity. Atherosclerosis 323:44\u201353. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2021.03.008","journal-title":"Atherosclerosis"},{"key":"2906_CR46","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1111\/j.1743-6109.2011.02311.x","volume":"8","author":"J Ott","year":"2011","unstructured":"Ott J, Aust S, Promberger R, Huber JC, Kaufmann U (2011) Cross-sex hormone therapy alters the serum lipid profile: a retrospective cohort study in 169 transsexuals. J Sex Med 8:2361\u20132369. https:\/\/doi.org\/10.1111\/j.1743-6109.2011.02311.x","journal-title":"J Sex Med"},{"key":"2906_CR47","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40618-023-02220-2","volume":"47","author":"D Santi","year":"2024","unstructured":"Santi D, Spaggiari G, Marinelli L, Cacciani M, Scipio S, Bichiri A et al (2024) Gender-affirming hormone treatment: friend or foe? Long-term follow-up of 755 transgender people. J Endocrinol Invest 47:1091\u2013100. https:\/\/doi.org\/10.1007\/s40618-023-02220-2","journal-title":"J Endocrinol Invest"},{"key":"2906_CR48","doi-asserted-by":"publisher","first-page":"E128","DOI":"10.1093\/eurjpc\/zwab075","volume":"29","author":"M Hilvo","year":"2022","unstructured":"Hilvo M, Dhar I, L\u00e4\u00e4peri M, Lysne V, Sulo G, Tell GS et al (2022) Primary cardiovascular risk prediction by LDL-cholesterol in Caucasian middle-aged and older adults: a joint analysis of three cohorts. Eur J Prev Cardiol 29:E128-37. https:\/\/doi.org\/10.1093\/eurjpc\/zwab075","journal-title":"Eur J Prev Cardiol"},{"key":"2906_CR49","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.52572","volume":"7","author":"G Yang","year":"2024","unstructured":"Yang G, Mason AM, Wood AM, Schooling CM, Burgess S (2024) Dose-response associations of lipid traits with coronary artery disease and mortality. JAMA Netw Open 7:E2352572. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.52572","journal-title":"JAMA Netw Open"},{"key":"2906_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fnut.2023.1162079","author":"L Yang","year":"2023","unstructured":"Yang L, Huang H, Liu Z, Ruan J, Xu C (2023) Association of the android to gynoid fat ratio with nonalcoholic fatty liver disease: a cross-sectional study. Front Nutr. https:\/\/doi.org\/10.3389\/fnut.2023.1162079","journal-title":"Front Nutr"},{"key":"2906_CR51","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0895-4356(96)00423-4","volume":"50","author":"M Yamada","year":"1997","unstructured":"Yamada M, Wong FL, Kodama K, Sasaki H, Shimaoka K, Yamakido M (1997) Longitudinal trends in total serum cholesterol levels in a Japanese cohort, 1958\u20131986. J Clin Epidemiol 50:425\u2013434. https:\/\/doi.org\/10.1016\/S0895-4356(96)00423-4","journal-title":"J Clin Epidemiol"},{"key":"2906_CR52","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-021627","volume":"8","author":"E Marzetti","year":"2018","unstructured":"Marzetti E, Calvani R, Picca A, Sisto A, Tosato M, Martone AM et al (2018) Prevalence of dyslipidaemia and awareness of blood cholesterol levels among community-living people: results from the Longevity check-up 7+ (Lookup 7+) cross-sectional survey. BMJ Open 8:e021627. https:\/\/doi.org\/10.1136\/bmjopen-2018-021627","journal-title":"BMJ Open"},{"key":"2906_CR53","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1177\/2047487315589011","volume":"22","author":"S Giampaoli","year":"2015","unstructured":"Giampaoli S, Palmieri L, Donfrancesco C, Noce lo C, Pilotto L, Vanuzzo D (2015) Cardiovascular health in Italy. Ten-year surveillance of cardiovascular diseases and risk factors: Osservatorio Epidemiologico Cardiovascolare\/Health Examination Survey 1998\u20132012. Eur J Prev Cardiol 22:9\u201337. https:\/\/doi.org\/10.1177\/2047487315589011","journal-title":"Eur J Prev Cardiol"},{"key":"2906_CR54","doi-asserted-by":"publisher","first-page":"4260","DOI":"10.1210\/jc.2016-1276","volume":"101","author":"AD Fisher","year":"2016","unstructured":"Fisher AD, Castellini G, Ristori J, Casale H, Cassioli E, Sensi C et al (2016) Cross-sex hormone treatment and psychobiological changes in transsexual persons: two-year follow-up data. J Clin Endocrinol Metab 101:4260\u20139. https:\/\/doi.org\/10.1210\/jc.2016-1276","journal-title":"J Clin Endocrinol Metab"},{"key":"2906_CR55","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1159\/000525792","volume":"15","author":"C Stival","year":"2022","unstructured":"Stival C, Lugo A, Odone A, van den Brandt PA, Fernandez E, Tigova O et al (2022) Prevalence and correlates of overweight and obesity in 12 European countries in 2017\u20132018. Obes Facts 15:655\u201365. https:\/\/doi.org\/10.1159\/000525792","journal-title":"Obes Facts"},{"key":"2906_CR56","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.endonu.2015.02.001","volume":"62","author":"C Quir\u00f3s","year":"2015","unstructured":"Quir\u00f3s C, Patrascioiu I, Mora M, Aranda GB, Hanzu FA, G\u00f3mez-Gil E et al (2015) Effect of cross-sex hormone treatment on cardiovascular risk factors in transsexual individuals. Experience in a specialized unit in Catalonia. Endocrinol Nutr 62:210\u20136. https:\/\/doi.org\/10.1016\/j.endonu.2015.02.001","journal-title":"Endocrinol Nutr"},{"key":"2906_CR57","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1210\/jc.2018-02138","volume":"104","author":"DM Van Velzen","year":"2019","unstructured":"Van Velzen DM, Paldino A, Klaver M, Nota NM, Defreyne J, Hovingh KG et al (2019) Cardiometabolic effects of testosterone in transmen and estrogen plus cyproterone acetate in transwomen. J Clin Endocrinol Metab 104:1937\u201347. https:\/\/doi.org\/10.1210\/jc.2018-02138","journal-title":"J Clin Endocrinol Metab"},{"key":"2906_CR58","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvad040","volume":"7","author":"FS Cunha","year":"2023","unstructured":"Cunha FS, Bachega TASS, Costa EMF, Brito VN, Alvares LA, Costa-Hong VA et al (2023) Arterial stiffness in transgender men receiving long-term testosterone therapy. J Endocr Soc 7:bvad040. https:\/\/doi.org\/10.1210\/jendso\/bvad040","journal-title":"J Endocr Soc"},{"key":"2906_CR59","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jsxm.2021.01.185","volume":"18","author":"C Cocchetti","year":"2021","unstructured":"Cocchetti C, Castellini G, Iacuaniello D, Romani A, Maggi M, Vignozzi L et al (2021) Does gender-affirming hormonal treatment affect 30-year cardiovascular risk in transgender persons? A two-year prospective European study (ENIGI). J Sex Med 18:821\u20139. https:\/\/doi.org\/10.1016\/j.jsxm.2021.01.185","journal-title":"J Sex Med"},{"key":"2906_CR60","doi-asserted-by":"publisher","first-page":"4206","DOI":"10.1210\/jc.2004-0631","volume":"89","author":"A Garg","year":"2004","unstructured":"Garg A (2004) Regional adiposity and insulin resistance. J Clin Endocrinol Metab 89:4206\u20134210. https:\/\/doi.org\/10.1210\/jc.2004-0631","journal-title":"J Clin Endocrinol Metab"},{"key":"2906_CR61","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2023-003412","author":"A Mohammad","year":"2023","unstructured":"Mohammad A, Ziyab AH, Mohammad T (2023) Anthropometric and DXA-derived measures of body composition in relation to pre-diabetes among adults. BMJ Open Diabetes Res Care. https:\/\/doi.org\/10.1136\/bmjdrc-2023-003412","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2906_CR62","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pharmthera.2012.03.007","volume":"135","author":"AA Knowlton","year":"2012","unstructured":"Knowlton AA, Lee AR (2012) Estrogen and the cardiovascular system. Pharmacol Ther 135:54\u201370. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.03.007","journal-title":"Pharmacol Ther"},{"key":"2906_CR63","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1161\/CIRCRESAHA.116.307509","volume":"118","author":"CL Blenck","year":"2016","unstructured":"Blenck CL, Harvey PA, Reckelhoff JF, Leinwand LA (2016) The importance of biological sex and estrogen in rodent models of cardiovascular health and disease. Circ Res 118:1294\u20131312. https:\/\/doi.org\/10.1161\/CIRCRESAHA.116.307509","journal-title":"Circ Res"},{"key":"2906_CR64","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.maturitas.2022.07.005","volume":"165","author":"E Kapoor","year":"2022","unstructured":"Kapoor E, Faubion SS, Gazzuola Rocca L, Mielke MM, Smith CY, Rocca WA (2022) Trajectories of metabolic parameters after bilateral oophorectomy in premenopausal women. Maturitas 165:38\u201346. https:\/\/doi.org\/10.1016\/j.maturitas.2022.07.005","journal-title":"Maturitas"},{"key":"2906_CR65","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3109\/13697137.2011.562994","volume":"14","author":"T Yoshida","year":"2011","unstructured":"Yoshida T, Takahashi K, Yamatani H, Takata K, Kurachi H (2011) Impact of surgical menopause on lipid and bone metabolism. Climacteric 14:445\u2013452. https:\/\/doi.org\/10.3109\/13697137.2011.562994","journal-title":"Climacteric"},{"key":"2906_CR66","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1093\/jsxmed\/qdad031","volume":"20","author":"FW Grimstad","year":"2023","unstructured":"Grimstad FW, Fraiman E, Garborcauskas G, Ferrando CA (2023) Retrospective review of changes in testosterone dosing and physiologic parameters in transgender and gender-diverse individuals following hysterectomy with and without oophorectomy. J Sex Med 20:690\u2013698. https:\/\/doi.org\/10.1093\/jsxmed\/qdad031","journal-title":"J Sex Med"},{"key":"2906_CR67","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1093\/ejendo\/lvaf183","volume":"193","author":"F Bonnet","year":"2025","unstructured":"Bonnet F, Vaduva P, Balkau B, Genet T, de Freminville JB, Ducluzeau P-H et al (2025) Testosterone therapy and the risk of atrial fibrillation, venous thromboembolism and cardiovascular events in cis men with hypogonadism and trans men. Eur J Endocrinol 193:374\u201382. https:\/\/doi.org\/10.1093\/ejendo\/lvaf183","journal-title":"Eur J Endocrinol"},{"key":"2906_CR68","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/nejmoa2215025","volume":"389","author":"AM Lincoff","year":"2023","unstructured":"Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE et al (2023) Cardiovascular safety of testosterone-replacement therapy. N Engl J Med 389:107\u201317. https:\/\/doi.org\/10.1056\/nejmoa2215025","journal-title":"N Engl J Med"},{"key":"2906_CR69","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1093\/jsxmed\/qdae138","volume":"21","author":"DR Greenberg","year":"2024","unstructured":"Greenberg DR, Kohn TP, Asanad K, Brannigan RE, Halpern JA (2024) Association of testosterone replacement therapy with atrial fibrillation and acute kidney injury. J Sex Med 21:1201\u20131203. https:\/\/doi.org\/10.1093\/jsxmed\/qdae138","journal-title":"J Sex Med"},{"key":"2906_CR70","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004880","author":"R Sharma","year":"2017","unstructured":"Sharma R, Oni OA, Gupta K, Sharma M, Sharma R, Singh V et al (2017) Normalization of testosterone levels after testosterone replacement therapy is associated with decreased incidence of atrial fibrillation. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/JAHA.116.004880","journal-title":"J Am Heart Assoc"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02906-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-026-02906-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-026-02906-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T06:08:44Z","timestamp":1787292524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-026-02906-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":70,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["2906"],"URL":"https:\/\/doi.org\/10.1007\/s40618-026-02906-3","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.A., A.L., A.D., A.F.G.C., A.S., R.S. and M.C.M. report no conflict of interest for this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}